Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "Lupin"

351 News Found

Briefs: Ipca Laboratories, Lupin and Zydus
News | June 05, 2023

Briefs: Ipca Laboratories, Lupin and Zydus

The company has extended its full co-operation and support to the officials of the Income Tax Department


Lupin receives USFDA approval from Obeticholic Acid Tablets
Drug Approval | June 01, 2023

Lupin receives USFDA approval from Obeticholic Acid Tablets

Obeticholic Acid Tablets had estimated annual sales of US$ 262 million in the U.S. (IQVIA MAT Mar 2023).


Lupin Diagnostics Launches Satellite Laboratory in Vijayawada
News | May 26, 2023

Lupin Diagnostics Launches Satellite Laboratory in Vijayawada

Continues to Expand its Presence in South India


Lupin posts Q4FY23 consolidated PAT up at Rs. 235.96 Cr
News | May 10, 2023

Lupin posts Q4FY23 consolidated PAT up at Rs. 235.96 Cr

The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023


Lupin to acquire French pharmaceutical company Medisol
News | May 07, 2023

Lupin to acquire French pharmaceutical company Medisol

The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU


Lupin receives tentative approval from USFDA for Valbenazine capsules
Drug Approval | March 28, 2023

Lupin receives tentative approval from USFDA for Valbenazine capsules

Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).


Lupin announces completion of pharmacovigilance inspection by USFDA
Drug Approval | March 27, 2023

Lupin announces completion of pharmacovigilance inspection by USFDA

The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide


Lupin announces successful completion of UK MHRA inspection of Pithampur facilities
Drug Approval | March 27, 2023

Lupin announces successful completion of UK MHRA inspection of Pithampur facilities

With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility of the company


Lupin receives tentative approval from USFDA for Obeticholic Acid Tablets
Drug Approval | March 24, 2023

Lupin receives tentative approval from USFDA for Obeticholic Acid Tablets

Obeticholic Acid Tablets (RLD Ocaliva) had estimated annual sales of US $255 million in the US (IQVIA MAT December 2022).


Lupin receives approval from USFDA for Brexpiprazole Tablets
Drug Approval | March 22, 2023

Lupin receives approval from USFDA for Brexpiprazole Tablets

Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)